Citation Impact
Citing Papers
The 2.6 Angstrom Crystal Structure of a Human A 2A Adenosine Receptor Bound to an Antagonist
2008 StandoutScience
Modeling Parkinson's Disease in Primates: The MPTP Model
2011
In VitroPermeability of PBCA Nanoparticles through Porcine Small Intestine
1993
Non-motor symptoms of Parkinson's disease: diagnosis and management
2006 Standout
Molecular mechanisms of L-DOPA-induced dyskinesia
2008
Parkinson disease
2017 Standout
Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease
2006
Wearable biosensors for healthcare monitoring
2019 Standout
Levodopa motor complications in Parkinson's disease
2000
Neuromolecular imaging, a nanobiotechnology for Parkinson’s disease: advancing pharmacotherapy for personalized medicine
2016
Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications
2003 Standout
The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
2009
Adenosine receptors as therapeutic targets
2006 Standout
Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats
2001
An investigation of whether there are sex differences in certain behavioural and neurochemical parameters in the rat
2012
Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat
2002 Standout
Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges
2004
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease
2005
New therapies for the treatment of Parkinson's disease: Adenosine A2A receptor antagonists
2005
Psychedelics
2016 Standout
Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects
2011 Standout
The CB1 Cannabinoid Receptor Agonist, HU‐210, Reduces Levodopa‐Induced Rotations in 6‐Hydroxydopamine‐Lesioned Rats
2003
Nonhuman Primates: A Critical Role in Current Disease Research
2001
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications
2014
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism
2003
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update
2011 Standout
CB cannabinoid receptor signalling in Parkinson’s disease
2003
Parkinson's disease
2009 Standout
Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
2004
Alterations in opioid receptor binding in Parkinson's disease patients with levodopa‐induced dyskinesias
1997
Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases
2015 Standout
Gut microbiome and health: mechanistic insights
2022 Standout
Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice
2005
Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease
2016 Standout
Environmental exposure to microplastics: An overview on possible human health effects
2019 Standout
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
2011
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
Cannabinoid Control of Motor Function at the Basal Ganglia
2005
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
2001
Extracellular matrix structure
2015 Standout
The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner
2012 Standout
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
2015 Standout
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
2011 Standout
N-Acyl-N-carboxymethyl-2-nitroaniline and its analogues: a new class of water-soluble photolabile precursor of carboxylic acids
2011
Perinatal Caffeine, Acting on Maternal Adenosine A1 Receptors, Causes Long-Lasting Behavioral Changes in Mouse Offspring
2008
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias
2003
Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinson’s Disease
2010
Modulators of the urokinase-type plasminogen activation system for cancer
2010
Novel pharmacological targets for the treatment of Parkinson's disease
2006
Physiology and Pathophysiology of Purinergic Neurotransmission
2007 Standout
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues
2008 Standout
Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study
1999
Drug transfer through mucus
2001
Parkinson's Disease
1998 Standout
The molecular logic of endocannabinoid signalling
2003 Standout
Non-motor features of Parkinson disease
2017 Standout
The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices
2000 Standout
Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
2006
Hindered diffusion of high molecular weight compounds in brain extracellular microenvironment measured with integrative optical imaging
1993
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors
2005
β-Phenylethylamines and the isoquinoline alkaloids
2006 Standout
Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias
2004
In vivo evaluation of matrix granules containing microcrystalline chitosan as a gel-forming excipient
2002
Nondopaminergic mechanisms in levodopa‐induced dyskinesia
2005
Theoretical Model for Water Diffusion in Tissues
1995 Standout
Striatal Cannabinoid CB1 Receptor mRNA Expression Is Decreased in the Reserpine-Treated Rat Model of Parkinson's Disease
2001
Adenosine receptors and l-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach
2003
Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model
2000
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
2013 Standout
Renal clearance of quantum dots
2007 StandoutNobel
Antibody diffusion in human cervical mucus
1994
Cannabinoids and the expanded endocannabinoid system in neurological disorders
2019
From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease
2010
Diffusion of Drugs in Native and Purified Gastrointestinal Mucus
1997
2015 StandoutNobel
Recent trends in the development of diagnostic tools for diabetes mellitus using patient saliva
2017
Synthesis of H-Pyrazolo[5,1-a]isoquinolines via Copper(II)-Catalyzed Oxidation of an Aliphatic C−H Bond of Tertiary Amine in Air
2011
3d Transition Metals for C–H Activation
2018 Standout
Photoremovable Protecting Groups in Chemistry and Biology: Reaction Mechanisms and Efficacy
2012 Standout
Toxic Potential of Materials at the Nanolevel
2006 StandoutScience
A Mitochondrial Paradigm of Metabolic and Degenerative Diseases, Aging, and Cancer: A Dawn for Evolutionary Medicine
2005 Standout
Clearance Properties of Nano-Sized Particles and Molecules as Imaging Agents: Considerations and Caveats
2008 Standout
Mechanisms of macromolecule absorption by the lungs
1996
Cp*Co(iii )-catalyzed, N–N bond-based redox-neutral synthesis of isoquinolines
2016
Parenteral protein delivery systems using biodegradable polyesters of ABA block structure, containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethylene oxide) B blocks
1996
Light microscopical observations on luminally administered dyes, dextrans, nanospheres and microspheres in the pre-epithelial mucus gel layer of the rat distal colon
1997
Diabetes and Cancer
2010 Standout
Towards the Relational Construction of Militant Particularisms: Or Why the Geographies of Past Struggles Matter for Resistance to Neoliberal Globalisation
2005 Standout
Long oligonucleotide microarrays for African green monkey gene expression profile analysis
2007 StandoutNobel
Aerobic Copper-Catalyzed Organic Reactions
2013 Standout
The Good City
2006 Standout
Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 21. Novel 4-Alkoxy and 14-Phenylpropoxy Derivatives of the μ Opioid Receptor Antagonist Cyprodime
2004
Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions
2016 Standout
Plastic and Human Health: A Micro Issue?
2017 Standout
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1
2011
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
2001 Standout
Chitosan Chemistry and Pharmaceutical Perspectives
2004 Standout
Diffusion of Macromolecules and Virus-Like Particles in Human Cervical Mucus
2001
Ingested Microscopic Plastic Translocates to the Circulatory System of the Mussel, Mytilus edulis (L.)
2008 Standout
A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease
2005
Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles
2005 Standout
Works of Brian Henry being referenced
Characterisation of human saliva as a platform for oral dissolution medium development
2015
Phencyclidine (PCP)-Induced Disruption in Cognitive Performance is Gender-Specific and Associated with a Reduction in Brain-Derived Neurotrophic Factor (BDNF) in Specific Regions of the Female Rat Brain
2010
Evaluation of the Intelisite capsule to deliver theophylline and frusemide tablets to the small intestine and colon
2001
Chapter 8 Chemical signalling in the globus pallidus in parkinsonism
1993
Can light absorption and photostability data be used to assess the photosafety risks in patients for a new drug molecule?
2009
Neural mechanisms underlying peak‐dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan
2001
Topographical Organization of Opioid Peptide Precursor Gene Expression Following Repeated Apomorphine Treatment in the 6-Hydroxydopamine-Lesioned Rat
1998
μ- and δ-Opioid Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's Disease
2001
The ?2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions ofL-dopa in the MPTP-lesioned primate model of Parkinson's disease
1999
Effect of Repeatedl-DOPA, Bromocriptine, or Lisuride Administration on Preproenkephalin-A and Preproenkephalin-B mRNA Levels in the Striatum of the 6-Hydroxydopamine-Lesioned Rat
1999
Characterization of Enhanced Behavioral Responses tol-DOPA Following Repeated Administration in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease
1998
Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
2002
Potential of Opioid Antagonists in the Treatment of Levodopa-Induced Dyskinesias in Parkinson??s Disease
1996
Gel permeation chromatography used to determine the stability of FITC-Dextrans in human saliva and porcine small intestinal mucus
1991
Selective Urokinase-Type Plasminogen Activator Inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines
2007
Epi-fluorescence Microscopy and Image Analysis Used to Measure Diffusion Coefficients in Gel Systems
1992
Dublin Hanged: Crime, Law Enforcement and Punishment in Late Eighteenth-Century Dublin.
1995